Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission File Number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 52-2210438 (State o ...

MaxCyte (MXCT) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the MaxSite First Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question, please press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that tod ...

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights Exhibit 99.1 "MaxCyte ...

ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights "MaxCyte has had a good start to 2025, with core revenue growth in the first quarter driven by continued strength ...

Company Overview - MaxCyte, Inc. is a leading company focused on cell engineering, providing platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics [1][3] - The company has over 25 years of expertise in building best-in-class platforms and innovating solutions for the cell therapy market [3] Financial Results Announcement - MaxCyte will release its financial results for the first quarter of 2025 after the U.S. market closes on May 7, 2025 [1] - A conference call to discuss these financial results will be hosted by company management at 4:30 p.m. Eastern Time on the same day [1] Conference Call Registration - Investors interested in the conference call must register online, with a recommendation to do so at least a day in advance [2] - A live and archived webcast of the event will be available on the MaxCyte website [2]

A downtrend has been apparent in MaxCyte, Inc. (MXCT) lately with too much selling pressure. The stock has declined 27.8% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, f ...

MaxCyte, Inc. (MXCT) has been on a downward spiral lately with significant selling pressure. After declining 30.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a s ...

MaxCyte, Inc. (MXCT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings ...

Alberto holds a Master's degree in Business Economics. During his academic career he acquired an extensive managerial and economic background, with a solid quantitative basis. He covers all sectors and the different types of stocks. Essentially describes a useful investment strategy that fits the profile of any investor, whether they are dividend investors or interested in a value proposition or growth opportunity.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the ...

Financial Data and Key Metrics Changes - Total revenue for the full year 2024 was $38.6 million, a 6% decline from $41.3 million in 2023 [28] - Total revenue in Q4 2024 was $8.7 million, representing a 45% decline from $15.7 million in Q4 2023 [28] - Core revenue for Q4 2024 was $8.6 million, an increase of 20% compared to $7.2 million in the prior year [28] - Core revenue for the full year 2024 was $32.5 million, up 9% from $29.8 million in 2023 [30] - Gross margin for Q4 2024 was 74%, down from 90% in Q4 2023 [33] Business Line Data and Key Metrics Changes - Instrument revenue for Q4 2024 was $1.6 million, down from $2.3 million in Q4 2023 [29] - License revenue for Q4 2024 was $2.6 million, slightly up from $2.4 million in Q4 2023 [29] - Processing assembly (PA) revenue for Q4 2024 was $4.2 million, significantly up from $2.2 million in Q4 2023 [29] - For the full year 2024, instrument revenue was $7.1 million, down from $8.3 million in 2023 [30] - PA revenue for the full year 2024 was $14 million, up from $10.3 million in 2023 [30] Market Data and Key Metrics Changes - As of the end of 2024, there were 28 active SPL customers, including 18 active clinical programs and one commercial program [15] - The total pre-commercial milestone potential across SPL agreements is greater than $2 billion [15] - The total pre-commercial milestone potential for the 18 active clinical programs is greater than $220 million, with about $10 million already received [16] Company Strategy and Development Direction - The acquisition of SeQure Dx is seen as a strategic move to enhance safety assessments in cell and gene therapy development [9] - The company aims to become a premier end-to-end cell and gene engineering platform, providing a comprehensive suite of offerings [12] - The focus remains on organic and inorganic investments that offer the best outcomes for customers while maintaining a healthy balance sheet [26] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2025, expecting an improvement in the funding environment for customers [14] - The company is committed to maintaining a streamlined organization to support long-term growth [37] - Management noted that the operational changes made in 2024 have positioned the company well for future growth [8] Other Important Information - The company ended 2024 with $190.3 million in cash and cash equivalents, with no debt [34] - The guidance for 2025 includes expected core revenue growth of 8% to 15%, inclusive of revenue from SeQure Dx [35] Q&A Session Summary Question: Guidance for Core business excluding SeQure Dx - Management indicated continued growth across the customer base and operational changes that should support year-over-year growth [41][42] Question: Revenue track record for SeQure Dx - SeQure Dx is expected to grow modestly in 2025, with a fee-for-service business model currently in place [46][49] Question: Integration costs for SeQure Dx - Integration costs are expected to be immaterial, leveraging existing commercial infrastructure [58][60] Question: Exposure to academic markets and NIH spending - The company's exposure to NIH grants is minimal, with no significant impact expected in the short term [64] Question: SPL environment and customer agreements - Most customers are still signing agreements at the pre-IND level, indicating a healthy business environment [68] Question: Combined company gross margins post-SeQure integration - Management expects combined gross margins to remain in the low to mid-80s [80] Question: Potential upside to top-line numbers for 2025 - The guidance is conservative, not assuming significant market recovery, but there is potential for upside if conditions improve [82][96]